Ron Nixon: Yeah, the Ross quite candidly, the valuations in the market typically don’t impact us because we are not a company that spends a lot of time in the process of bidding on other companies. What we are looking for is alignment of interest from other partners out there that may have a complementary business to what we offer. And so therefore we ended up in more of a negotiated transaction. If you see from our past with how we handled the Precision Healing, how we handled Scendia, how we’ve handled the WounDerm and WounDime and Pixalere all of those acquisitions involve stock and cash. Not all of them actually had cash, but most of those had that componentry. But what it was, was alignment of interest of two parties where their technology would advance our strategy.
And they saw that we had the entire comprehensive strategy as opposed to a single component. And so either they sought that out or we found them in the marketplace and did a negotiated transaction. We anticipate more of that in the future, not less of that.
Ross Osborn: Got it. Thank you for taking my questions and congrats on the progress.
Ron Nixon: Hey, thank you very much, Ross.
Operator: Thank you. Our next question is coming from Ian Cassel with IFCM. Please go ahead.
Ian Cassel: Yeah, I was wondering if you could talk a bit about the BIASURGE opportunity. You know, I’m just curious about the market opportunity itself, you know, if that’s a greenfield opportunity or if you’re displacing a competitor. And if so the latter, you know, what the competitive advantages are of BIASURGE.
Ron Nixon: Yeah. Zach, you want to take that?
Zachary Fleming: I’ll take that. Yeah, sure. So, yeah, we think that is somewhat of a greenfield opportunity. And here’s — here’s why we think that there are two competitors that have entered the market. One is called Irrisept. I believe that’s the Irrimax Corporation and then another is Bactisure. And there’s a few line extensions that have come from Bactisure and that’s the next science brand that Zimmer licensed. A couple of reasons. One, I think we fit in a price situation that will be very complementary or very complementary to Cellerate, but as well appropriate for the facilities. I think they’re going to appreciate where we will stand in the pricing realm. We also have a couple of distinct clinical advantages related to the other two products that are out in the market, and I think I’ll withhold those advantages for now until we do the launch.
But they will be distinct and noticeable to the clinician, and I think they’re going to give them a great advantage in the operating theatre. And then I think it does compliment Cellerate, so Cellerate being our lead product. That product does very well in clean ready to heal wounds. And so we want to be able to offer that. And so when you use a BIASURGE product, you’re cleaning the field, you’re reducing the bioburden in that wound, and then you can place the Cellerate and Cellerate will have a greater effect.
Ian Cassel: Thank you. My next question is just overall, I mean, Cellerate continues to grow really, really fast. And, you know, I’m just kind of curious, what are the challenges to continuing that growth rate, you know, for the company moving forward?
